Henry H. Armstrong Associates’s Pfizer PFE Stock Holding History

Henry H. Armstrong Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$371K	Hold	15,394	–	–	0.04%	50
2026 Q1	$432K	Hold	15,394	–	–	0.04%	48
2025 Q4	$383K	Hold	15,394	–	–	0.04%	49
2025 Q3	$392K	Hold	15,394	–	–	0.04%	49
2025 Q2	$373K	Sell	15,394 -500	-3%	-$11.7K	0.04%	48
2025 Q1	$403K	Hold	15,894	–	–	0.04%	47
2024 Q4	$422K	Sell	15,894 -1,148	-7%	-$31.1K	0.04%	45
2024 Q3	$493K	Sell	17,042 -700	-4%	-$20.4K	0.05%	49
2024 Q2	$496K	Sell	17,742 -280	-2%	-$7.71K	0.05%	45
2024 Q1	$500K	Sell	18,022 -300	-2%	-$8.32K	0.05%	43
2023 Q4	$527K	Sell	18,322 -5,873	-24%	-$178K	0.06%	41
2023 Q3	$803K	Hold	24,195	–	–	0.09%	34
2023 Q2	$887K	Sell	24,195 -700	-3%	-$27.2K	0.1%	33
2023 Q1	$1.02M	Hold	24,895	–	–	0.12%	33
2022 Q4	$1.28M	Hold	24,895	–	–	0.16%	32
2022 Q3	$1.09M	Hold	24,895	–	–	0.15%	32
2022 Q2	$1.3M	Sell	24,895 -366	-1%	-$18.7K	0.16%	32
2022 Q1	$1.31M	Buy	25,261 +182	+0.7%	+$9.44K	0.14%	32
2021 Q4	$1.48M	Hold	25,079	–	–	0.16%	36
2021 Q3	$1.08M	Buy	25,079 +325	+1%	+$14.4K	0.12%	40
2021 Q2	$969K	Hold	24,754	–	–	0.11%	41
2021 Q1	$897K	Hold	24,754	–	–	0.11%	40
2020 Q4	$911K	Sell	24,754 -1,231	-5%	-$45.2K	0.12%	40
2020 Q3	$905K	Hold	25,985	–	–	0.13%	37
2020 Q2	$806K	Buy	25,985 +551	+2%	+$18.7K	0.12%	38
2020 Q1	$788K	Buy	25,434 +632	+3%	+$21.5K	0.13%	39
2019 Q4	$922K	Buy	24,802 +13,175	+113%	+$469K	0.13%	42
2019 Q3	$396K	Hold	11,627	–	–	0.07%	38
2019 Q2	$478	Hold	11,627	–	–	0.07%	38
2019 Q1	$468K	Buy	11,627 +312	+3%	+$12.5K	0.07%	42
2018 Q4	$469K	Buy	11,315 +1,093	+11%	+$45.4K	0.08%	40
2018 Q3	$427K	Hold	10,222	–	–	0.07%	41
2018 Q2	$352K	Buy	10,222 +422	+4%	+$14.4K	0.06%	44
2018 Q1	$338K	Sell	9,800 -422	-4%	-$14.5K	0.06%	44
2017 Q4	$351K	Sell	10,222 -3,283	-24%	-$112K	0.06%	44
2017 Q3	$457K	Hold	13,505	–	–	0.08%	41
2017 Q2	$430K	Hold	13,505	–	–	0.08%	41
2017 Q1	$438K	Sell	13,505 -362	-3%	-$11.4K	0.08%	40
2016 Q4	$427K	Buy	13,867 +2,507	+22%	+$76.5K	0.09%	41
2016 Q3	$365K	Hold	11,360	–	–	0.07%	42
2016 Q2	$379K	Buy	11,360 +508	+5%	+$16.2K	0.08%	40
2016 Q1	$305K	Hold	10,852	–	–	0.06%	41
2015 Q4	$332K	Buy	10,852 +843	+8%	+$26.5K	0.07%	40
2015 Q3	$298K	Buy	10,009 +319	+3%	+$10.2K	0.06%	35
2015 Q2	$308K	Hold	9,690	–	–	0.07%	33
2015 Q1	$320K	Sell	9,690 -1,155	-11%	-$36.7K	0.07%	34
2014 Q4	$321K	Buy	10,845 +633	+6%	+$18.1K	0.07%	33
2014 Q3	$287K	Buy	10,212 +247	+2%	+$6.93K	0.07%	32
2014 Q2	$281K	Buy	9,965 +380	+4%	+$10.8K	0.07%	35
2014 Q1	$292K	Hold	9,585	–	–	0.07%	32
2013 Q4	$279K	Hold	9,585	–	–	0.06%	32
2013 Q3	$261K	Hold	9,585	–	–	0.07%	31
2013 Q2	$255K	Buy	+9,585	New	+$265K	0.07%	30

Other funds holding PFE

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

ORIO

Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Kepler Cheuvreux Nyon $1.75B AUM 37.37% 1-Year Est. Return

Henry H. Armstrong Associates's PFE Position: Q2 2026 in Review

Henry H. Armstrong Associates held its Pfizer (PFE) position steady in Q2 2026 at 15,394 shares worth $371K. The position accounts for 0.04% of the portfolio, ranked #50.

Henry H. Armstrong Associates first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.48M in Q4 2021. 644 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Henry H. Armstrong Associates held 15,394 shares of Pfizer worth $371K as of Q2 2026.
Henry H. Armstrong Associates left its Pfizer share count unchanged in Q2 2026.
Pfizer made up 0.04% of Henry H. Armstrong Associates's portfolio in Q2 2026, its #50 holding.
Henry H. Armstrong Associates first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Henry H. Armstrong Associates's Pfizer position peaked at $1.48M in Q4 2021.
644 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Henry H. Armstrong Associates's 13F filing for Q2 2026, filed 7 Jul 2026.